After years of delays and rising costs, AstraZeneca has formally unveiled its $1 billion R&D facility in Cambridge, said to be the biggest science lab of its kind in the UK.

AstraZeneca succeeded in thwarting Pfizer's takeover plans – but was forced to promise investors that it could deliver very rapid growth – forecasting revenues of $45 billion by 2023, compared ...